Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q1 FY22 results · Apr–Jun 2021
Neuland Laboratories reported revenue from operations of ₹200.89 crore (down 2.2% from Q1 FY21) and net profit of ₹8.73 crore (down 42.4% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 200.89 | 205.42 | −2.2% | 244.70 | −17.9% |
| Other income | 2.06 | 0.70 | +194.8% | 14.60 | −85.9% |
| Total income | 202.94 | 206.12 | −1.5% | 259.30 | −21.7% |
| Profit before tax | 12.07 | 20.31 | −40.6% | 24.39 | −50.5% |
| Net profit for the period | 8.73 | 15.16 | −42.4% | 17.29 | −49.5% |
| EPS, basic (₹) | 6.81 | 11.82 | −42.4% | 13.48 | −49.5% |
| Net margin (%) | 4.3 | 7.4 | 7.1 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 200.89 | 205.42 | −2.2% | 244.70 | −17.9% |
| Other income | 2.06 | 0.70 | +194.8% | 14.60 | −85.9% |
| Total income | 202.94 | 206.12 | −1.5% | 259.30 | −21.7% |
| Profit before tax | 11.99 | 20.20 | −40.7% | 24.32 | −50.7% |
| Net profit for the period | 8.65 | 15.06 | −42.6% | 17.23 | −49.8% |
| EPS, basic (₹) | 6.74 | 11.74 | −42.6% | 13.43 | −49.8% |
| Net margin (%) | 4.3 | 7.3 | 7.0 |
Consolidated
- Filed with BSE
- 03 Aug 2021, 17:15 IST
- Board meeting
- 03 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Aug 2021, 17:15 IST
- Board meeting
- 03 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE